Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Although there is a rising trend in both dengue cases and immunocompromised conditions, there is limited research on how common severe dengue is in immunocompromised individuals. This data is key for those advising the ever-increasing numbers of immunocompromised travellers.
Methods: We conducted a systematic review and meta-analysis of studies reporting dengue frequency or outcomes in immunocompromised populations. Non-human and review articles were excluded. Risk of bias was assessed using the ROBINS-E tool.
Results: Eighty-five studies were included, 63 had a very high risk of bias. Frequency of dengue among different immunocompromised patient cohorts varied from 0.3%-6.3%. Of 1182 dengue cases, 664 had autoimmune diseases, 388 were post-solid organ transplant (SOT), 20 post-stem cell transplant (HSCT), 28 had haematological malignancies, 24 non-haematological malignancies, and 58 were HIV-positive. Severe dengue and mortality were estimated at 0.27 [0.22-0.33] and 0.14 [0.10-0.18], decreasing to 0.16 [0.09-0.27] and 0.04 [0.03-0.05] when very high risk or small-sample studies were excluded. Twenty-three (5.6%) of post-transplant dengue patients were considered as donor-related. Mortality reached 66.7% in HSCT and 10% in SOT. Dengue RNA was detectable up to four months in blood, and up to two years in urine; viable virus was isolated from urine at nine months.
Conclusions: Dengue in immunocompromised, especially HSCT, is associated with high severity and mortality. It also has the potential for prolonged viral persistence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/jtm/taaf093 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dengue among immunocompromised patients: a systematic review and meta-analysis.
J Travel Med
September 2025
Vaccine Trial Centre, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Background: Although there is a rising trend in both dengue cases and immunocompromised conditions, there is limited research on how common severe dengue is in immunocompromised individuals. This data is key for those advising the ever-increasing numbers of immunocompromised travellers.
Methods: We conducted a systematic review and meta-analysis of studies reporting dengue frequency or outcomes in immunocompromised populations.
The modified mRNA vaccine protects immunocompromised AG129 mice from lethal challenge and multi-tissue infection by Zika virus.
Emerg Microbes Infect
September 2025
Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
The multiple epidemics of Zika virus (ZIKV) posed a substantial threat to public health. Clinical evidence suggests that ZIKV could break through the blood-brain, blood-placenta, and blood-testis barriers, leading to severe outcomes such as congenital malformations in newborns and Guillain-Barré syndrome in adults. Currently, there are no specific treatments for ZIKV infection.
View Article and Find Full Text PDFInvasive nasal and paranasal mucormycosis in a patient with severe dengue fever and multiple risk factors: A case report and literature review.
Med Mycol Case Rep
September 2025
Infectious Department, Hanoi Medical University, No. 1 Ton That Tung, Dong Da, Hanoi, Viet Nam.
Mucormycosis is a rare, life-threatening opportunistic fungal infection with high mortality rates that primarily affects immunocompromised patients. The co-occurrence of dengue fever and mucormycosis is extremely rare, with only a few cases reported worldwide. We report a case of a 50-year-old female diagnosed with mucormycos following dengue fever.
View Article and Find Full Text PDFChronic and reactivated dengue infection in an immunocompromised host: insights from a case report.
Trop Med Health
August 2025
Laboratoire de Microbiologie, CHU Réunion Site Nord, Saint-Denis, Réunion, France.
Background: Dengue, a viral infection transmitted by mosquitoes, is a growing global health concern, particularly as its spread now puts half of the world's population at risk. While dengue usually resolves after the primary infection, persistent or chronic cases can occur in immunocompromised individuals.
Case Presentation: This case study reports a 43-year-old woman with lupus nephritis and end-stage kidney disease who experienced symptomatic dengue reactivation nearly three years after her initial infection.
Prolonged dengue viremia with predominantly ocular manifestations in a lung transplant recipient.
BMC Infect Dis
August 2025
Department of Infectious Diseases, The Canberra Hospital, Canberra, ACT, Australia.
Background: The clinical manifestations of dengue are well-described, but ocular involvement is being increasingly recognized and alterations to the natural trajectory of disease, including protracted viraemia, have also been recognized in immunocompromised patients. We describe a case of dengue in a lung transplant recipient which manifested predominantly as ocular symptoms following short-lived systemic features, and with protracted viraemia with delayed IgM to IgG seroconversion.
Case Presentation: A 40-year-old woman who had a bilateral lung transplant 15 years prior for cystic fibrosis presented with headaches, bilateral scotomata and rapidly deteriorating visual acuity.